Durvalumab: A Review in Advanced Biliary Tract Cancer
Authors:
Open Access
- 9 November 2023
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 18 (6) , 965-972
Abstract
Durvalumab (Imfinzi®), a therapeutic human monoclonal antibody which binds to and blocks the activity of the immunosuppressive programmed death-ligand 1 (PD-L1) protein, is approved in the USA, EU, Japan and other countries in combination with gemcitabine and cisplatin for adults with advanced biliary tract cancer. In the pivotal phase 3 TOPAZ-1 trial, durvalumab plus gemcitabine and cisplatin significantly prolonged overall survival and progression-free survival compared with placebo plus gemcitabine and cisplatin in adults with advanced biliary tract cancer. Benefit from durvalumab was seen irrespective of primary tumour location, disease status at diagnosis (unresectable or recurrent), or initial levels of PD-L1 expression. The tolerability of durvalumab plus gemcitabine and cisplatin was manageable. Overall, the addition of durvalumab to gemcitabine and cisplatin is a valuable new treatment option for adults with advanced biliary tract cancer.Keywords
This publication has 20 references indexed in Scilit:
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialThe Lancet, 2019
- Emerging strategies in cancer therapy combining chemotherapy with immunotherapyCancer Letters, 2019
- Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease StatusClinical Pharmacology & Therapeutics, 2017
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaJAMA Oncology, 2017
- Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patientsCancer Chemotherapy and Pharmacology, 2017
- PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinomaOncology Letters, 2017
- Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal AntibodyCancer Immunology Research, 2015
- A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.Journal of Clinical Oncology, 2014
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanBritish Journal of Cancer, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010